Menu
← Oncology Approval Tracker
FDA DECISION ·
Pemetrexed Injection (Actavis) + cisplatin
pemetrexed plus cisplatin · Actavis
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Initial therapy with cisplatin for locally advanced or metastatic nonsquamous NSCLC, using the specified pemetrexed product.
LAMPGEN ANALYSIS
Why it matters
The supplement adds a cisplatin-based first-line indication separate from the same-day immunochemotherapy indication.
What research teams should watch
Check nonsquamous histology and distinguish this doublet from the pembrolizumab-based regimen.
PRIMARY RECORDS